Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics in Immunotherapy for Urothelial Bladder Carcinoma
NCT05220124Phase 4Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jan 2022
- Primary completion
- Nov 2024
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
A Phase 4 trial of nivolumab + nab-paclitaxel + carboplatin + Bifidobacterium Triple Viable in bladder urothelial carcinoma, sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
nivolumab + nab-paclitaxel + carboplatin + Bifidobacterium Triple Viable
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT05220124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220124.